Neuroinflammatory mediators in acquired epilepsy: an update

• Published in: Inflammation research Vol. 72; no. 4; pp. 683 - 701
• Main Authors: Chen, Yu, Nagib, Marwa M., Yasmen, Nelufar, Sluter, Madison N., Littlejohn, Taylor L., Yu, Ying, Jiang, Jianxiong
• Format: Journal Article
• Language: English
• Published: Cham Springer International Publishing 01.04.2023; Springer Nature B.V
• Subjects: Allergology; Astrocytes; Astrocytes - metabolism; Biomarkers; Biomedical and Life Sciences; Biomedicine; Blood-brain barrier; Brain - metabolism; Chemokines; Comorbidity; Convulsions & seizures; Dermatology; Epilepsy; Humans; Immunology; Inflammation; Inflammation - metabolism; Microglia; Neurological diseases; Neurology; Pharmacology/Toxicology; Review; Rheumatology; Seizures; Seizures - complications; Seizures - metabolism; Microsomal prostaglandin E synthase-1 (mPGES-1); Epileptogenesis; Biomarker; EP2; Cytokine; Status epilepticus (SE); Neuroinflammation; ); Prostaglandin E2 (PGE; Chemokine; Antiseizure drug (ASD); Cyclooxygenase 2 (COX-2); Seizure; High mobility group box 1 (HMGB1); Prostaglandin E2 (PGE2)
• ISSN: 1023-3830; 1420-908X
• DOI: 10.1007/s00011-023-01700-8

Epilepsy is a group of chronic neurological disorders that have diverse etiologies but are commonly characterized by spontaneous seizures and behavioral comorbidities. Although the mechanisms underlying the epileptic seizures mostly remain poorly understood and the causes often can be idiopathic, a considerable portion of cases are known as acquired epilepsy. This form of epilepsy is typically associated with prior neurological insults, which lead to the initiation and progression of epileptogenesis, eventually resulting in unprovoked seizures. A convergence of evidence in the past two decades suggests that inflammation within the brain may be a major contributing factor to acquired epileptogenesis. As evidenced in mounting preclinical and human studies, neuroinflammatory processes, such as activation and proliferation of microglia and astrocytes, elevated production of pro-inflammatory cytokines and chemokines, blood–brain barrier breakdown, and upregulation of inflammatory signaling pathways, are commonly observed after seizure-precipitating events. An increased knowledge of these neuroinflammatory processes in the epileptic brain has led to a growing list of inflammatory mediators that can be leveraged as potential targets for new therapies of epilepsy and/or biomarkers that may provide valued information for the diagnosis and prognosis of the otherwise unpredictable seizures. In this review, we mainly focus on the most recent progress in understanding the roles of these inflammatory molecules in acquired epilepsy and highlight the emerging evidence supporting their candidacy as novel molecular targets for new pharmacotherapies of acquired epilepsy and the associated behavioral deficits.